Cambridge companies help develop Covid antibody cocktail
1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article
Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]
UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease
29 September 2020 – Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence. Read full article
OBN Awards – Announcement of 2020 Finalists
11 September 2020 – OBN Award Finalists Read full article
Agile start-ups partner with academics to find COVID-19 solutions
16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, […]
Illumina unveils first Cambridge cohort for global genomics accelerator
23 June 2020 – Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator. Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK. Read full article
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
23 June 2020 – Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Read full article
Alchemab: One for the future and another first for Cambridge
4 June 2020 – A novel Cambridge UK life science startup – Alchemab Therapeutics – looks set for global glory by identifying and harnessing the power of naturally protective antibodies to combat a broad range of hard-to-treat diseases. Read full article
Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures
20 May 2020 – Alchemab’s publication illustrating progress in understanding patients’ immune responses to COVID19 which will help inform vaccination and antibody therapeutics. Read full article
How the U.K. healthcare sector is leveraging its strengths to beat COVID-19
1 May 2020 – Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K. life sciences industry is rising to the challenge with a mix of collaboration, speed, creativity and […]